CRL · NYSE
Charles River Laboratories International (CRL) Stock Price & Fundamentals
Charles River Laboratories International (CRL) closed at $697.91 on Oct 9, 2026, up 0.43% from the previous close of $694.92.
Share price, past year
1Y −0.12%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $697.91 |
| Sep 30, 2026 | $690.74 |
| Aug 31, 2026 | $678.32 |
| Jul 31, 2026 | $676.76 |
| Jun 30, 2026 | $713.01 |
| May 29, 2026 | $710.37 |
| Apr 30, 2026 | $708.98 |
| Mar 31, 2026 | $699.17 |
| Feb 27, 2026 | $739.28 |
| Jan 30, 2026 | $702.05 |
| Dec 31, 2025 | $714.96 |
| Nov 28, 2025 | $694.34 |
| Oct 31, 2025 | $706.22 |
Key statistics
- Market cap
- $33.31B
- P/E (TTM)
- —
- EPS (TTM)
- −$4.80
- Revenue (TTM)
- $4.00B
- Net income (TTM)
- −$238.46M
- Shares outstanding
- 47.7M
- Dividend yield
- —
- 52-week range
- $655.24 – $746.76
Charles River Laboratories International's market cap is $33.31B, based on a share price of $697.91 and 47.7M shares outstanding as of Jun 27, 2026.
Financials
Charles River Laboratories International reported revenue of $4.02B for fiscal 2025, down 0.85% from fiscal 2024.
Charles River Laboratories International reported a net loss of $144.34M in fiscal 2025.
Charles River Laboratories International's fiscal 2025 net loss was its first in at least 9 years.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 27, 2025 | $4.02B | −0.9% | −$144.34M | −3.6% | −$2.91 | — |
| FY2024ended Dec 28, 2024 | $4.05B | −1.9% | $22.20M | 0.6% | $0.20 | — |
| FY2023ended Dec 30, 2023 | $4.13B | +3.9% | $474.62M | 11.5% | $9.22 | — |
| FY2022ended Dec 31, 2022 | $3.98B | +12.3% | $486.23M | 12.2% | $9.48 | — |
| FY2021ended Dec 25, 2021 | $3.54B | +21.1% | $390.98M | 11.0% | $7.60 | — |
| FY2020ended Dec 26, 2020 | $2.92B | +11.6% | $364.30M | 12.5% | $7.20 | — |
| FY2019ended Dec 28, 2019 | $2.62B | +15.7% | $252.02M | 9.6% | $5.07 | — |
| FY2018ended Dec 29, 2018 | $2.27B | +22.0% | $226.37M | 10.0% | $4.62 | — |
| FY2017ended Dec 30, 2017 | $1.86B | +10.5% | $123.36M | 6.6% | $2.54 | — |
| FY2016ended Dec 31, 2016 | $1.68B | — | $154.77M | 9.2% | $3.23 | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 27, 2026 | $1.00B | −$1.48M | −$0.03 |
| Q1 FY2026ended Mar 28, 2026 | $995.83M | −$14.84M | −$0.30 |
| Q4 FY2025ended Dec 27, 2025 | $994.23M | −$276.56M | −$5.57 |
| Q3 FY2025ended Sep 27, 2025 | $1.00B | $54.42M | $1.10 |
| Q2 FY2025ended Jun 28, 2025 | $1.03B | $52.33M | $1.06 |
| Q1 FY2025ended Mar 29, 2025 | $984.17M | $25.47M | $0.50 |
| Q4 FY2024ended Dec 28, 2024 | $1.00B | −$214.50M | −$4.17 |
| Q3 FY2024ended Sep 28, 2024 | $1.01B | $69.66M | $1.33 |
Company profile
- Name
- Charles River Laboratories International, Inc.
- Ticker
- CRL
- Exchange
- NYSE
- Industry (SEC SIC)
- Services-Commercial Physical & Biological Research
- Headquarters
- 251 Ballardvale St, Wilmington, MA 01887
- Fiscal year ends
- December
- SEC CIK
- 0001100682
Recent SEC filings
- Sep 24, 2026
- Aug 5, 2026
- Aug 5, 2026
- May 11, 2026
- May 7, 2026
- May 7, 2026
- Feb 25, 2026
- Feb 18, 2026
Frequently asked questions
What is Charles River Laboratories International's stock price?
Charles River Laboratories International (CRL) closed at $697.91 on Oct 9, 2026, up 0.43% from the previous close of $694.92.
What is Charles River Laboratories International's market cap?
Charles River Laboratories International's market cap is $33.31B, based on a share price of $697.91 and 47.7M shares outstanding as of Jun 27, 2026.
How much revenue does Charles River Laboratories International make?
Charles River Laboratories International reported revenue of $4.02B for fiscal 2025, down 0.85% from fiscal 2024.
Does Charles River Laboratories International pay a dividend?
Charles River Laboratories International's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Charles River Laboratories International, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures